AstraZeneca's New Diabetes Drug Formulation Gets FDA Approval
October 23 2017 - 01:48AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) has received approval from the U.S.
Food and Drug Administration for a new formulation of its type-2
diabetes treatment option Bydureon, it said Monday.
The pharmaceutical company said that the regulator has given the
green light to its Bydureon BCise injectable suspension drug--a
single-dose autoinjector device that is used once a week. The new
formulation reduces blood sugar levels and has the added benefit of
weight loss, the company said.
AstraZeneca said the drug will be available to U.S. patients
from the first quarter of 2018.
The European Medicines Agency has also accepted an application
for the autoinjection, it added.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 23, 2017 02:33 ET (06:33 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024